PHP
Parkman Healthcare Partners Portfolio holdings
AUM
$864M
This Quarter Return
+20.97%
1 Year Return
+33.7%
3 Year Return
+258.24%
5 Year Return
+878.92%
10 Year Return
–
AUM
$815M
AUM Growth
+$815M
(+15%)
Cap. Flow
+$60M
Cap. Flow
% of AUM
7.37%
Top 10 Holdings %
Top 10 Hldgs %
31.52%
Holding
117
New
28
Increased
37
Reduced
32
Closed
17
Top Buys
| 1 |
Eli Lilly
LLY
|
$25M |
| 2 |
Cooper Companies
COO
|
$21.3M |
| 3 |
Fortrea Holdings
FTRE
|
$17.2M |
| 4 |
Schrodinger
SDGR
|
$16.1M |
| 5 |
Oscar Health
OSCR
|
$12.4M |
Top Sells
| 1 |
Amgen
AMGN
|
$17.7M |
| 2 |
Boston Scientific
BSX
|
$15.6M |
| 3 |
Keros Therapeutics
KROS
|
$12.1M |
| 4 |
Mettler-Toledo International
MTD
|
$9.1M |
| 5 |
Humana
HUM
|
$8.28M |
Sector Composition
| 1 | Healthcare | 99.46% |
| 2 | Industrials | 0.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Amicus Therapeutics
FOLD
$2.34B
| $2.67M | 0.33% | +226,723 | New | +$2.67M |
|
77
Insmed
INSM
$28.8B
| $2.52M | 0.31% | 93,032 -57,784 | -38% | -$1.57M |
|
78
SI-BONE Inc
SIBN
$719M
| $2.5M | 0.31% | 152,781 +7,206 | +5% | +$118K |
|
79
Annexon
ANNX
$226M
| $2.49M | 0.31% | +346,687 | New | +$2.49M |
|
80
Viking Therapeutics
VKTX
$3.04B
| $2.48M | 0.3% | +30,298 | New | +$2.48M |
|
81
TG Therapeutics
TGTX
$4.65B
| $2.36M | 0.29% | 155,039 -50,278 | -24% | -$765K |
|
82
Acumen Pharmaceuticals
ABOS
$82.4M
| $2.34M | 0.29% | 576,657 -26,840 | -4% | -$109K |
|
83
VYNE Therapeutics
VYNE
$8.16M
| $2.14M | 0.26% | 696,470 | – | – |
|
84
ESSA Pharma
EPIX
$11.4M
| $2.14M | 0.26% | +251,695 | New | +$2.14M |
|
85
89bio
ETNB
$1.34B
| $2.09M | 0.26% | 179,899 -39,549 | -18% | -$460K |
|
86
Reviva Pharmaceuticals
RVPH
$30.6M
| $1.9M | 0.23% | +503,854 | New | +$1.9M |
|
|
CDMO
87
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $1.81M | 0.22% | +270,136 | New | +$1.81M |
|
|
INZY
88
DELISTED
Inozyme Pharma
INZY
| $1.71M | 0.21% | 222,943 +10,511 | +5% | +$80.5K |
|
89
Ardelyx
ARDX
$1.53B
| $1.46M | 0.18% | +200,000 | New | +$1.46M |
|
90
Cytokinetics
CYTK
$4.23B
| $1.41M | 0.17% | +20,160 | New | +$1.41M |
|
91
X4 Pharmaceuticals
XFOR
$84.2M
| $1.12M | 0.14% | 805,359 +38,027 | +5% | +$52.9K |
|
92
SOPHiA GENETICS
SOPH
$234M
| $1.03M | 0.13% | 209,896 +9,899 | +5% | +$48.8K |
|
93
Butterfly Network
BFLY
$405M
| $810K | 0.1% | +750,000 | New | +$810K |
|
94
Alpha Teknova
TKNO
$231M
| $785K | 0.1% | 296,202 +13,966 | +5% | +$37K |
|
95
NovoCure
NVCR
$1.38B
| $782K | 0.1% | +50,000 | New | +$782K |
|
96
Eton Pharmaceutcials
ETON
$464M
| $747K | 0.09% | 199,168 | – | – |
|
97
TELA Bio
TELA
$70.5M
| $554K | 0.07% | 97,668 -5,707 | -6% | -$32.4K |
|
|
THRD
98
DELISTED
Third Harmonic Bio
THRD
| $378K | 0.05% | +40,000 | New | +$378K |
|
99
Xeris Biopharma Holdings
XERS
$1.26B
| $222K | 0.03% | +100,676 | New | +$222K |
|
|
100
Amgen
AMGN
$155B
| – | – | -61,524 | Closed | -$17.7M |
|